SCHEMBL963712

SCHEMBL963712

Nc1ncc(Cc2ccc(F)cc2)s1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.70
POLB P06746 2/20 0.64
TSHR P16473 1/20 0.60
ALDH1A1 P00352 4/20 0.49
TDP1 Q9NUW8 2/20 0.49
MAPT P10636 2/20 0.49
THRB P10828 1/20 0.49
HTT P42858 1/20 0.49
RECQL P46063 1/20 0.49
HSD17B10 Q99714 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SMN1; SMN2 Q16637 5/20 0.46
HPGD P15428 2/20 0.46
LMNA P02545 2/20 0.46
GAA P10253 1/20 0.46
OPRK1 P41145 1/20 0.46
CCR6 P51684 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6803163 0.85 EPHX2 (0.74) EPHX2POLBTSHRALDH1A1TDP1
SCHEMBL4015123 0.84 EPHX2 (0.50) EPHX2POLBTSHRALDH1A1TDP1
SCHEMBL27674641 0.82 EPHX2 (0.70) EPHX2POLBTSHRALDH1A1TDP1
SCHEMBL14341905 0.82 EPHX2 (1.00) EPHX2POLBTSHRALDH1A1TDP1
SCHEMBL231214 0.82 EPHX2 (0.70) EPHX2POLBTSHRALDH1A1TDP1
SCHEMBL3136047 0.82 EPHX2 (0.70) EPHX2POLBTSHRALDH1A1TDP1
SCHEMBL21384166 0.82 EPHX2 (0.56) EPHX2POLBTSHRALDH1A1TDP1
SCHEMBL231242 0.81 EPHX2 (0.69) EPHX2POLBTSHRALDH1A1TDP1
SCHEMBL29442859 0.81 EPHX2 (0.59) EPHX2POLBTSHRALDH1A1TDP1
SCHEMBL21384040 0.81 EPHX2 (0.59) EPHX2POLBTSHRALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4662211-A1 G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) DEGRADATION COMPOUNDS AND USE THEREOF Nanjing Huanbo Biotechnology Co., Ltd. (CN) 2025-12-17 EP disclosed
CN-114845709-B MRGPRX2 antagonists for the treatment of inflammatory disorders 德米拉公司 2024-10-01 CN disclosed
WO-2024165075-A1 G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) DEGRADATION COMPOUNDS AND USE THEREOF NANJING HUANBO BIOTECHNOLOGY CO., LTD. (CN) 2024-08-15 WO disclosed
US-11993595-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2024-05-28 US disclosed
US-20230052191-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2023-02-16 US disclosed
US-20230052191-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2023-02-16 US disclosed
US-11472798-B2 Compounds MISSION THERAPEUTICS LTD (GB) 2022-10-18 US disclosed
EP-4054554-A1 MRGPRX2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS Dermira, Inc (US) 2022-09-14 EP disclosed
CN-114845709-A MRGPRX2 antagonists for use in treating inflammatory disorders 德米拉公司 2022-08-02 CN disclosed
EP-3828179-A1 CYANOPYRROLIDINES AS DUB MODULATORS Mission Therapeutics Limited (GB) 2021-06-02 EP disclosed
US-7595398-B2 N-(5-membered aromatic ring)-amido anti-viral compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-09-29 US disclosed
WO-2009085256-A1 ANTI-HIV COMPOUNDS PANACOS PHARMACEUTICALS, INC. (US) 2009-07-09 WO disclosed
WO-2009085256-A1 ANTI-HIV COMPOUNDS PANACOS PHARMACEUTICALS, INC. (US) 2009-07-09 WO disclosed
CN-101448800-A Novel compounds as cannabinoid receptor ligands and uses thereof ABBOTT LAB (US) 2009-06-03 CN disclosed
EP-2024349-A2 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF Abbott Laboratories (US) 2009-02-18 EP disclosed
EP-1971597-A2 N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. (US) 2008-09-24 EP disclosed
US-20080064699-A1 Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection ABBVIE INC. 2008-03-13 US disclosed
WO-2007140439-A2 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBOTT LABORATORIES (US) 2007-12-06 WO disclosed
US-20070265265-A1 N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. 2007-11-15 US disclosed
WO-2007070600-A2 N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11472798-B2 Compounds UCHL1, UCHL3, UCHL5 EPHX2 2019/4885POLB 2709/4885TSHR 3585/4885
US-11993595-B2 Compounds UCHL1, UCHL3, UCHL5 EPHX2 2019/4885POLB 2709/4885TSHR 3585/4885
US-20080064699-A1 Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection OPRL1, OPRK1, OPRD1 EPHX2 437/4885POLB 4650/4885TSHR 2499/4885
US-20230052191-A1 NOVEL COMPOUNDS UCHL1, UCHL3, UCHL5 EPHX2 2077/4885POLB 2561/4885TSHR 3406/4885
US-20070265265-A1 N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS ZC3HAV1, ZC3HAV1L, HAVCR2 EPHX2 3478/4885POLB 1018/4885TSHR 2330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.